Team:Arizona State/MHC

From 2013.igem.org

(Difference between revisions)
Line 18: Line 18:
</p>
</p>
-
<h3>MHC Pathway presentation Depends Upon Pathogenic characteristics</h3>
+
<h3>MHC Class I Pathway Presentation Depends Upon Pathogenic Characteristics</h3>
 +
<p>
 +
The immune system has two separate pathways within antigen-presenting immune cells (APCs) that trigger immune responses. The Major Histocompatibility Complex (MHC) Class I Pathway activated CD8, or Cytotoxic, T lymphocytes. The MHC Class I protein complex is present on all human cells and is the complex that changes during tumor development. Activated of CD8 T cells with an antigen present on an MHC Class I Protein Complex allows them to selectively target tumor cells expressing that same antigen on their surface.
 +
</p>
<h3>Expression of Lysteriolysin in E.coli Nissile can confer difference in MHC presentation</h3>
<h3>Expression of Lysteriolysin in E.coli Nissile can confer difference in MHC presentation</h3>

Revision as of 23:10, 27 September 2013

Recombinant expression of FluM1 from Influenza & Melan-A from Melanoma provides protein epitope for antigen recognition

The BactoVax vaccine platform has been engineered to act as a general vaccine platform, suitable for vaccination against bacteria, viruses, and tumors. Our current system has been engineered to express both viral antigen FluM1 and cancer surface antigen Melan-A to illustrate the modular nature of the platform itself. Instead of having to engineer a separate vaccine for every single different strain of a particular disease or group of disease separately, BactoVax provides a chassis that can be easily modified simply by addition of the nucleotide sequence for antigen of interest to trigger a specialized immune response.

MHC Class I Pathway Presentation Depends Upon Pathogenic Characteristics

The immune system has two separate pathways within antigen-presenting immune cells (APCs) that trigger immune responses. The Major Histocompatibility Complex (MHC) Class I Pathway activated CD8, or Cytotoxic, T lymphocytes. The MHC Class I protein complex is present on all human cells and is the complex that changes during tumor development. Activated of CD8 T cells with an antigen present on an MHC Class I Protein Complex allows them to selectively target tumor cells expressing that same antigen on their surface.

Expression of Lysteriolysin in E.coli Nissile can confer difference in MHC presentation